Hilltop Partners’s AbbVie ABBV Stock Holding History

Hilltop Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$921K	Sell	3,659 -29	-0.8%	-$6.24K	0.22%	64
2026 Q1	$802K	Buy	3,688 +66	+2%	+$14.6K	0.21%	58
2025 Q4	$828K	Buy	3,622 +35	+1%	+$7.97K	0.21%	56
2025 Q3	$831K	Buy	3,587 +6	+0.2%	+$1.22K	0.25%	55
2025 Q2	$665K	Sell	3,581 -215	-6%	-$40K	0.2%	62
2025 Q1	$795K	Sell	3,796 -24	-0.6%	-$4.67K	0.27%	53
2024 Q4	$679K	Sell	3,820 -43	-1%	-$7.91K	0.23%	60
2024 Q3	$763K	Buy	3,863 +4	+0.1%	+$747	0.26%	59
2024 Q2	$662K	Buy	3,859 +55	+1%	+$9.11K	0.24%	58
2024 Q1	$693K	Buy	3,804 +2	+0.1%	+$345	0.25%	57
2023 Q4	$589K	Buy	3,802 +123	+3%	+$17.9K	0.23%	55
2023 Q3	$548K	Sell	3,679 -15	-0.4%	-$2.2K	0.23%	57
2023 Q2	$498K	Buy	3,694 +615	+20%	+$90.2K	0.21%	61
2023 Q1	$491K	Buy	3,079 +6	+0.2%	+$917	0.22%	41
2022 Q4	$497K	Buy	+3,073	New	+$471K	0.27%	30

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Hilltop Partners's ABBV Position: Q2 2026 in Review

Hilltop Partners reduced its AbbVie (ABBV) stake by 0.79% in Q2 2026, selling an estimated $6.24K and leaving 3,659 shares worth $921K. The position accounts for 0.22% of the portfolio, ranked #64.

Hilltop Partners first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Hilltop Partners held 3,659 shares of AbbVie worth $921K as of Q2 2026.
Hilltop Partners sold 29 AbbVie shares in Q2 2026, an estimated $6.24K.
AbbVie made up 0.22% of Hilltop Partners's portfolio in Q2 2026, its #64 holding.
Hilltop Partners first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Hilltop Partners's 13F filing for Q2 2026, filed 5 Aug 2026.